The National Institute for Health and Clinical Trials (NICE) approved the variable is a new drug MabThera treatment for rheumatoid arthritis (RA) in England and Wales. The principle of the drug is to block one of the key immune damages in this severe disease.

This happened after another similar drug was excluded from the protocols of RA treatment. The concluding findings of NICE recommend the use of MabThera in patients who do not respond to standard therapy, according to an online edition for girls and women aged 14 to 35 Pannochka.

Net Rheumatoid arthritis is a severe autoimmune disease, accompanied by damage to cartilage and bone tissue and resulting in decreased joint mobility and severe pain syndrome.

In clinical trials, more than a third of patients indicated a reduction in symptoms of rheumatoid arthritis after prima MabThera. As some participants of the study stated, the drug gives a chance to improve the condition of patients with severe forms of RA and should be used to treat this serious disease.

Medicinform. Net.

Keywords:.